Last reviewed · How we verify

NCT05605236: Stereotactic

Stereotactic Margins in Localized Bronchial Cancer (T1/T2a, N0)

Completed Last updated 14 December 2023
What this trial tests

trial in Bronchial Cancer in 300 participants. Completed in 16 July 2022.

Timeline
16 February 2020
Primary endpoint
16 May 2022
16 July 2022

Quick facts

Lead sponsorUniversity Hospital, Strasbourg, France
StatusCompleted
Study typeOBSERVATIONAL
Enrollment300
Start date16 February 2020
Primary completion16 May 2022
Estimated completion16 July 2022
Sites1 location across France

Conditions studied

Sponsor

University Hospital, Strasbourg, France

Who can join

18 and older, any sex, with Bronchial Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Bronchopulmonary cancer is the first cause of mortality in the world. We want to update the margins used in stereotactic radiotherapy, in the context of localized lung cancer, of non-surgical management. The investigators wish to redefine the stereotactic radiotherapy margins according to the histological type in localized non-small cell lung cancer. Indeed, these criteria were previously defined on a smaller cohort, in the context of 3D radiotherapy (mainly T3, T4 tumors). In addition, the incidence of radiation pneumonitis is highly dependent on the irradiated lung volume, which in turn depends on the CTV margins used.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Bronchial Cancer

Currently open trials in the same condition.

Other University Hospital, Strasbourg, France trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05605236.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing